A Phase II Trial of Combination Bisphosphonate and Antiangiogenesis Therapy With Pamidronate and Thalidomide in Patients with Smoldering/Indolent Myeloma

II

To evaluate the effectiveness of combination treatment with thalidomide and pamidronate in patients with smoldering or indolent myeloma

• No bisphosphonate therapy within 30 days prior to study entry
• No prior treatment for hypercalcemia within 2 weeks of study entry
• No severe heart disease, unstable thyroid disease, or epilepsy
• Limited prior radiation

Patients receive oral thalidomide once a day. Thalidomide dose may be reduced and/or taken once every other day depending on patient tolerance. Patients receive pamidronate by IV every 2 weeks for 2 months. Disease is reassessed after 2 months, and depending on patient response, maintenance therapy may include daily thalidomide and pamidronate once every 4 weeks. Disease is reassessed every 3 months while on maintenance, and treatment may continue

Arkansas
University of Arkansas for Medical Sciences
Cherie L. Harless, BS, CCRP
Supervisor MIRT Data Management
Clinical Research Associate
QA & Industry Trials
Myeloma Institute for Research and Therapy
4301 W. Markham St. / Slot 815
Little Rock, Ar. 72205-7199
Phone : 501-296-1503 Ext.1463
Fax : 501-686-5831
HarlessCherieL@uams.edu